India Pharma Outlook Team | Monday, 19 January 2026
Sun Pharmaceutical Industries has started the commercial launch of its cancer medication, Unloxcyt, in the United States market.
This is a significant development for the Indian pharmaceutical company in the international market for cancer treatment.
The medication, known by the brand name Unloxcyt (cosibelimab-ipdl) in the market, has been made available for prescription by doctors for the treatment of adults who have metastatic or locally advanced cutaneous squamous cell carcinoma (aCSCC) and cannot receive curative therapy.
Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies
The launch has come after the United States FDA approved an updated labeling for Unloxcyt based on long-term clinical data that has shown durable responses with a good tolerability profile. The results of the pivotal studies have shown meaningful objective responses with sustained disease control in a number of patients, supporting the drug’s utility for advanced skin cancer.
“Unloxcyt is an evolution in checkpoint inhibition, combining durable efficacy with a proven tolerability profile for a group of aCSCC patients who traditional would struggle to strike that therapeutic balance,” said Richard Ascroft, CEO , Sun Pharma North America.
Sun Pharma introduced support services for patients and healthcare practitioners, which not only shows the commitment to enhance care delivery from Day One but is an important aspect to consider.
Industry observers believe that Unloxcyt’s foray into the U.S. market, apart from meeting an urgent and unserved need for patients with advanced skin cancers, will further enhance Sun Pharma’s specialty offerings as they continue to diversify and move away from their traditional focus on generics and into innovative and high-value products.
.jpg)
.jpg)
